CY1108098T1 - Διαγνωστικη μεθοδος για την προβλεψη της απορριψης μεταμοσχευσεων νεφρου - Google Patents

Διαγνωστικη μεθοδος για την προβλεψη της απορριψης μεταμοσχευσεων νεφρου

Info

Publication number
CY1108098T1
CY1108098T1 CY20071101331T CY071101331T CY1108098T1 CY 1108098 T1 CY1108098 T1 CY 1108098T1 CY 20071101331 T CY20071101331 T CY 20071101331T CY 071101331 T CY071101331 T CY 071101331T CY 1108098 T1 CY1108098 T1 CY 1108098T1
Authority
CY
Cyprus
Prior art keywords
diagnostic method
transplant rejection
renal transplant
predicting renal
predicting
Prior art date
Application number
CY20071101331T
Other languages
English (en)
Inventor
Andrea Galli
Paola Romagnani
Mario Serio
Calogero Surrenti
Original Assignee
Universita' Degli Studi Di Firenze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita' Degli Studi Di Firenze filed Critical Universita' Degli Studi Di Firenze
Publication of CY1108098T1 publication Critical patent/CY1108098T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Abstract

Η παρούσα εφεύρεση αφορά νέες θεραπευτικές εφαρμογές φαρμακευτικών σκευασμάτων που περιέχουν, ως δραστικά στοιχεία, θειαζολιδινοδιόνες, για τη θεραπεία ή πρόληψη νόσων που χαρακτηρίζονται από αύξηση στα επίπεδα της ΙΡ-10, όπως Πρωτογενής Χοληφόρος Κίρρωση, οξεία και χρόνια απόρριψη μεταμόσχευσης νεφρού και παγκρεατικών νησίδων και ενδοκρινείς αυτοάνοσες ασθένειες. Η εφεύρεση επίσης αφορά διαγνωστική μέθοδο για την πρόβλεψη της απόρριψης μεταμοσχεύσεων νεφρού με χρήση των προ της μεταμόσχευσης επιπέδων της ΙΡ-10 ως δείκτη ορού.
CY20071101331T 2003-03-06 2007-10-15 Διαγνωστικη μεθοδος για την προβλεψη της απορριψης μεταμοσχευσεων νεφρου CY1108098T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000058A ITFI20030058A1 (it) 2003-03-06 2003-03-06 Formulazioni farmaceutiche contenenti tiazolidinedioni
EP04716242A EP1601355B1 (en) 2003-03-06 2004-03-02 Diagnostic method for prevision of kidney transplantation rejection

Publications (1)

Publication Number Publication Date
CY1108098T1 true CY1108098T1 (el) 2014-02-12

Family

ID=32948189

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101331T CY1108098T1 (el) 2003-03-06 2007-10-15 Διαγνωστικη μεθοδος για την προβλεψη της απορριψης μεταμοσχευσεων νεφρου

Country Status (14)

Country Link
US (1) US20060287372A1 (el)
EP (2) EP1601355B1 (el)
JP (1) JP2006519799A (el)
AT (1) ATE368859T1 (el)
AU (1) AU2004216823B2 (el)
CA (1) CA2518199A1 (el)
CY (1) CY1108098T1 (el)
DE (1) DE602004007895T2 (el)
DK (1) DK1601355T3 (el)
ES (1) ES2290678T3 (el)
IT (1) ITFI20030058A1 (el)
PL (1) PL1601355T3 (el)
PT (1) PT1601355E (el)
WO (1) WO2004078175A2 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
ITFI20040243A1 (it) * 2004-11-25 2005-02-25 Paola Romagnani Metodo diagnostico per la previsione di rigetto di organo trapiantato
GB0504206D0 (en) * 2005-03-01 2005-04-06 Glaxo Group Ltd Combination therapy
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
PL2001469T3 (pl) 2006-03-16 2012-10-31 Metabolic Solutions Dev Co Llc Analogi tiazolidynodionu
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200927731A (en) 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
BRPI0920354A2 (pt) 2008-10-16 2017-06-27 Addex Pharmaceuticals Sa derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
US20190350907A1 (en) * 2017-01-16 2019-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0767790B1 (en) * 1994-06-20 2001-12-12 Takeda Chemical Industries, Ltd. Condensed imidazole compounds, their production and use
KR20000016074A (ko) * 1996-05-31 2000-03-25 가와무라 요시부미 자기면역질환 치료제
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
WO2000030628A2 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
US6369098B1 (en) * 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
CA2393136A1 (en) * 1999-11-30 2001-06-07 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
WO2001062238A2 (en) * 2000-02-24 2001-08-30 San Diego State University Ppar gamma agonists for the treatment of liver inflammatory disorders
US20020019344A1 (en) * 2000-02-26 2002-02-14 Pershadsingh Harrihar A. Methods of preventing allograft rejection
US20020018776A1 (en) * 2000-04-14 2002-02-14 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CXCR3 function
FR2823225B1 (fr) * 2001-04-04 2004-09-17 Pierre Desreumaux Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant
US7244555B2 (en) * 2002-05-14 2007-07-17 Renovak Inc Systems and methods for identifying organ transplant risk

Also Published As

Publication number Publication date
WO2004078175A2 (en) 2004-09-16
DE602004007895T2 (de) 2008-04-17
EP1601355A2 (en) 2005-12-07
ATE368859T1 (de) 2007-08-15
US20060287372A1 (en) 2006-12-21
EP1830191A2 (en) 2007-09-05
DK1601355T3 (da) 2007-12-17
PL1601355T3 (pl) 2007-12-31
EP1830191A3 (en) 2007-10-03
DE602004007895D1 (de) 2007-09-13
WO2004078175A3 (en) 2004-12-09
JP2006519799A (ja) 2006-08-31
ES2290678T3 (es) 2008-02-16
EP1601355B1 (en) 2007-08-01
PT1601355E (pt) 2007-11-15
AU2004216823A1 (en) 2004-09-16
ITFI20030058A1 (it) 2004-09-07
CA2518199A1 (en) 2004-09-16
AU2004216823B2 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
CY1108098T1 (el) Διαγνωστικη μεθοδος για την προβλεψη της απορριψης μεταμοσχευσεων νεφρου
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
DE602004020332D1 (de) Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DK1131096T3 (da) Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
ATE457989T1 (de) Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE60225561D1 (de) Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung
ATE313540T1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE383854T1 (de) Kombination ausgewählter opioide mit muscarin- antagonisten zur therapie der harninkontinenz
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
DE602004020042D1 (de) er SSRI zur Behandlung von Stimmungs- oder Angststörungen
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
DE60207612D1 (de) Verbindungen zur bilddarstellung der alzheimer-krankenheit
NZ546440A (en) Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
IL159479A (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind